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and molecular content (2). While the release of bacterial 
EVs is predominantly by direct outward “blebbing” and 
pinching of the external cellular membranes (2) in eukary-
otic cells, EVs are generated both at the plasma mem-
brane [ectosomes, also called shed microparticles or 
microvesicles (MVs)] or inside multivesicular bodies (MVBs) 
(exosomes) through two membrane inversion processes: 
the inward budding of the limiting membrane of the mul-
tivesicular endosome to form intraluminal vesicles and the 
fusion of MVBs with the plasma membrane. As a result, 
both ectosomes and exosomes have the same membrane 
topology of donor cells. However, EVs, especially ecto-
somes, often lose transmembrane lipid asymmetry and 
have phosphatidylserine (PS) residues externalized in the 
outer leaflet of the vesicle (3–5).
Plasma membrane-derived EVs are on average larger 
than exosomes in size, ranging from 100 to 300 nm up to 
1 m, while exosomes are generally 30–100 nm in diame-
ter and are isolated by centrifugation at higher speeds com-
pared with ectosomes (100,000 g vs. 10,000 g). Both types of 
EVs are recognized as mediators of cell-to-cell communica-
tion due to their ability to transfer biomolecules among cells 
(6–9) and to influence the extracellular microenvironment 
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via regulation of critical nutrients (10, 11). EVs not only 
serve several physiological functions, such as neurotrophic 
support (12, 13) and disposal of unwanted cellular compo-
nents (14), but also play pathophysiological roles in inflam-
matory and degenerative diseases (15–17). Therefore, 
inhibiting the biogenesis and release of EVs may be an im-
portant therapeutic goal, as recently outlined by Tricarico, 
Clancy, and D’Souza-Schorey (18).
The mechanism of EV biogenesis has been a matter of 
intense research in the recent years. For discussion of 
the role of proteins, including members of the endosomal 
sorting complex required for transport (ESCRT), small 
GTPases, and glutaminase, in both exo- and ectosome bio-
genesis and fission, we refer readers to these other excel-
lent reviews (18, 19). Here, we focus on the involvement of 
sphingolipids (SLs) and their metabolic enzymes in the 
biogenesis and release of ectosomes and exosomes, which 
has received less attention.
SLs are a class of lipids located in the plasma membrane 
and at intracellular organelle membranes, which have not 
only structural roles but also signaling function. Ceramide 
(Cer) and sphingosine-1-phosphate (S1P) are the main 
SLs that act as signaling molecules, controlling a vast num-
ber of cellular processes, such as cell growth, adhesion, 
migration, senescence, cell death, and inflammatory re-
sponse (20–22). In these cellular activities, dynamic balance 
between S1P and Cer levels is crucial. This process is known 
as “SL rheostat” (23).
SLs are constituted by a sphingoid base. In bilayer-
forming SLs, a fatty acid is tethered/covalently linked to 
the sphingoid base. All SLs may be modified at the first 
hydroxyl group with a variable polar head group, and also 
by an esterified fatty acid tethered to the amino group of 
the sphingosine (Sph).
Cer, composed of a long-chain amino alcohol, known as 
Sph, linked to an amide bond to a long-chain fatty acid, is 
the structural unit of membrane-forming SLs (not present 
in Sph and S1P), which represent the most abundant SLs 
in cells. Cer, can originate from “de novo synthesis,” degra-
dation of complex SLs (24), or recycling of long-chain 
bases through a salvage pathway (21, 25). The “de novo” 
biosynthesis of SLs begins with the condensation of palmi-
toyl-CoA with l-serine to form sphinganine and dihydroc-
eramide, respectively, after reduction and acylation. In the 
de novo biosynthesis, dihydroceramide is then desaturated 
with the consequent formation of Cer. All of the enzymes 
involved in the de novo biosynthesis of Cer are localized in 
the endoplasmic reticulum (ER) membrane and act on the 
cytosolic surface of this subcellular organelle. The prod-
ucts of the reactions that are catalyzed by these enzymes 
remain anchored to the ER. In the salvage pathway, Cer is 
synthesized from Sph (26). During the degradation of 
complex SLs, glycosphingolipids (GSLs) are constitutively 
degraded to monosaccharides and Cer (27, 28), while SM 
is degraded to Cer and phosphocholine (29).
Once generated, Cer can be cleaved by a ceramidase 
(CDase) to generate Sph that, in turn, can be phosphory-
lated for the synthesis of the crucial bioactive SL, S1P. On 
the other hand, Cer is a substrate for various enzymes, 
mainly by the addition of phosphocholine to produce SM 
or by the addition of monosaccharides to produce GSLs. 
Among GSLs, gangliosides are a particular class character-
ized by the presence of one or more sialic acid residues 
(26). The GSLs, together with simple SLs, are located in 
the plasma membrane, where they interact with growth 
factor receptors, integrins, and other key molecules that 
participate in cell-cell and cell-matrix interactions (30). 
Importantly, several SL metabolites have been associated 
with development of several pathologies, including diabe-
tes, cancer, microbial infections, neurological syndromes, 
and cardiovascular disease (21, 25, 26, 31–35).
In this review, we will critically summarize current knowl-
edge on the action of SL-metabolizing enzymes in the for-
mation and release of the two main types of EVs (ectosomes 
and exosomes) as well as past and current efforts in target-
ing these enzymes pharmacologically or genetically for 
therapeutic purposes. We then focus on the SL content of 
EVs and discuss the molecular mechanisms underlying the 
capability of EVs to promote SL metabolism in target cells.
ROLE OF SLs IN EXOSOME AND ECTOSOME 
RELEASE
Cer-dependent exosome biogenesis: role for neutral 
SMase
Plasma and endosomal membranes display an asymmet-
ric lipid distribution, with SM and phosphatidylcholine 
(PC) enriched on the noncytosolic (luminal) side, and PS 
and other lipid classes enriched in the leaflet facing cytosol 
(36). Consolidated evidence indicates that changing the lo-
cal lipid composition is a way to alter the membrane fluid-
ity and curvature. For example, breakdown of SM, which 
has a high affinity for membrane cholesterol (37), results 
in increased efflux of cholesterol from the membrane and 
increased membrane fluidity (38, 39), while generation of 
Cer, which has a cone-shaped structure, can give a sponta-
neous curvature to the membrane (40) (Fig. 1A).
SM is hydrolyzed into phosphorylcholine and Cer by the 
action of SMases, a family of enzymes that possesses acid, 
neutral, or alkaline optimal pH (41). Neutral SMase (n-SMase) 
2, also known as SM phosphodiesterase (SMPD)3, mostly 
localizes to the Golgi and ER (42), while n-SMase 1, also 
called SMPD2, is localized to the Golgi and nucleus (43, 
44). However, plasma membrane-associated n-SMases have 
also been characterized (45, 46), and n-SMase 2 has been 
reported to recycle via the endosomal/recycling compart-
ment (42). Activity of n-SMases is present at the cytosolic 
leaflet of the membrane (45). By contrast, acid SMase 
(a-SMase) activity is present in lysosomes and on the outer 
plasma membrane leaflet following lysosome fusion to the 
cell membrane (47).
Membrane destabilization driven by SM hydrolysis was 
initially reported to play a key role in membrane blebbing 
and release of apoptotic bodies during the late phase of cell 
damage (48). In 2002, Nurminen et al. (49) visualized the 
macroscopic consequence of SM breakdown by SMases on 
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lipid membrane using fluorescence and differential interfer-
ence contrast microscopy. SMase was immobilized onto syn-
thetic microspheres and brought into contact with a giant 
liposome membrane by a micromanipulator: the contact 
caused formation of membrane microdomains and subse-
quent shedding of small vesicles from the membrane into 
the interior of the giant liposome (49). This elegant study 
was followed in 2008 by the seminal work by Trajokovic et al. 
(50), who first described that SM hydrolysis and Cer forma-
tion participate in ESCRT-independent biogenesis of intra-
luminal vesicles inside MVBs, the vesicles that are released 
as exosomes upon MVB fusion with the plasma membrane. 
While investigating sorting mechanisms of protein cargo 
into exosomes in an oligodendrocyte cell line (oli-Neu), 
Trajkovic et al. (50) observed that total Cer was enriched 
more than 3-fold in a subpopulation of exosomes containing 
proteolipid protein (PLP). The role of Cer in the biogenesis 
and release of PLP-positive exosomes was analyzed by treat-
ing Oli-neu cells with GW4869, an inhibitor of n-SMase 1 
and n-SMase 2, and two structurally unrelated n-SMase 
blockers, spiroepoxide and glutathione. Exosome release 
was markedly reduced after treatment of the cells with all 
the n-SMase inhibitors. siRNA depletion of n-SMase 2 con-
firmed the involvement of the enzyme in the formation and 
secretion of PLP-positive exosomes. On this basis, Trajkovic 
et al. (50) proposed a lipid-based mechanism for mem-
brane bending and exosome formation. They proposed 
that biogenesis of PLP-positive exosomes occurs at mem-
brane domains enriched in SLs through formation of Cer 
microdomains and their coalescence into larger domains, 
which promote inward vesicle budding (50) (Fig. 1A). The 
cone-shaped structure of Cer induces spontaneous nega-
tive curvature to the membrane of endosomes and favors 
formation of internal vesicles inside MVBs.
Fig. 1. MV and exosome biogenesis: the role of SMase and its product Cer. A: On the left, SM (cylinder shaped) stabilizes membrane 
structure; on the right, when a-SMase translocates from the lysosomal compartment to the outer leaflet of the plasma membrane, SM hydro-
lysis and Cer accumulation into the inner leaflet of the plasma membrane favor blebbing and MV evagination, thanks to the inverted cone 
shape of Cer. B: n-SMase resides on the cytosolic leaflet of endosomes/MVBs. As in A, before n-SMase action SM stabilizes membrane struc-
ture, while Cer production by n-SMase induces spontaneous negative curvature to the membrane of endosomes, thus promoting the forma-
tion of internal vesicles inside MVBs.
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Subsequent in vitro works reported that, while exoge-
nous cell permeable C6 Cer dose-dependently increases 
the number of exosomes released from multiple myeloma 
cells (51), pharmacological or genetic block of n-SMase in-
hibited packaging of the prion protein into exosomes (52) 
and reduced exosome release among others in HEK cells 
(53), T cells (54), N2a cells (55), astrocytes (56), microglia 
(57), macrophages (58), hepatocytes (59), and multiple 
myeloma cells (51). Also, in vivo, in the brain and serum of 
5XFAD mice, a transgenic model of Alzheimer’s disease 
(AD), the n-SMase inhibitor, GW4869, decreased exosome 
concentration (60). Importantly, decreased exosome pro-
duction was reported by the same group in 5XFAD mice 
crossed with fro/fro mice, which lack n-SMase 2 (61), con-
firming the enzyme involvement in exosome release. Con-
versely, elevation of Cer caused by block of Cer conversion 
to SM by the SM synthase inhibitor, D609, promoted exo-
some secretion (55, 60).
In agreement with these studies, it has recently been 
shown that basal exosome production can be influenced by 
cellular components that control n-SMase activity. For ex-
ample, in hepatocytes, the chemokine receptor, CXCR2, 
negatively regulates n-SMase activity and cells lacking 
CXCR2 expression produce significantly more exosomes 
than wild-type hepatocytes (62). Interestingly, inhibition of 
exosome release by CXCR2 is unrelated to ligand binding 
to the receptor and may occur in endosomal membranes 
where n-SMase localizes and exosomes are generated (62).
Collectively, these studies led to the idea that Cer is im-
portant for exosome release in general. However, exo-
somes are a heterogeneous population of vesicles and it is 
important to remember that blocking of n-SMases does not 
block release of all exosomes or impair exosome biogene-
sis in all the cells tested (63–65), as recently highlighted by 
Skotland, Sandvig, and Llorente (66).
S1P-dependent cargo sorting in exosomes
Trajkovic et al. (50) revealed a role for Cer in exosome 
formation by inward budding inside MVBs. However, the 
mechanism underlying cargo sorting remained unan-
swered. A recent discovery by Nakamura’s group provided 
new insights into mechanisms of both Cer-dependent exo-
some formation and cargo sorting (67). Kajimoto et al. 
(67) initially showed that exosomal formation inside MVBs 
depends on S1P, the Cer metabolite generated by sequen-
tial activity of CDase and Sph kinase (SK). Specifically, they 
demonstrated that the S1P type 1 receptor (S1P1), an in-
hibitory G protein-coupled receptor, is present on MVBs 
and its sustained activation controls exosomal maturation 
and cargo sorting in HEK cells. In fact, downregulation of 
either S1P1 or the S1P synthesizing enzyme, SK-2, decreased 
CD63, CD81, and flotilin-2 content in exosomes (67). In a 
subsequent study, the same group further dissected the 
molecular mechanism necessary for cargo sorting by show-
ing that downstream signaling of S1P1, mediated by the  
and  subunits of the inhibitory G protein (Gi), con-
stantly activates the Rho family GTPases, Cdc42 and rac1, 
on MVBs. Through this mechanism, S1P promotes forma-
tion of F-actin networks that are essential for cargo sorting 
in exosomes. This is indicated by decreased content of 
CD63 in exosomes released under pharmacological inhibi-
tion of both F-actin and S1P formation (68).
Does n-SMase control biogenesis of MVs at the plasma 
membrane?
Until very recently, the action of n-SMase activity had 
been explored in the biogenesis of exosomes, but not in a 
larger EV population, such as MVs (69). The only study 
that analyzed the impact of n-SMase inhibitors on MV se-
cretion from the plasma membrane was conducted on pri-
mary microglia under stimulation with ATP (70), a stimulus 
particularly effective in promoting release of both ecto-
somes and exosomes from brain immune cells (57, 71). 
This work showed no changes in ATP-induced MV shed-
ding under pharmacological block of n-SMase by GW4869 
or manumicyn, another n-SMase inhibitor, revealing that 
n-SMase activity is not required for ATP-induced MV shed-
ding at the cell surface (70).
Recently, Menck et al. (69) investigated the effects of 
n-SMase on basal MV production from epithelial cells. Using 
pharmacological and genetic inhibitors of n-SMases, they 
observed an increase rather than a decrease in ectosome 
release from the cell surface. Consistently, overexpression 
of n-SMases (SMPD2 or SMPD3) decreased MV shedding 
(69). Although further work is necessary to define the 
mechanisms underlying enhanced MV production under 
block of n-SMase, this study clearly showed that n-SMase 
differentially controls the release of exosomes and MVs in 
epithelial cells. Enhanced basal MV production in cells 
treated with GW4869, a common tool to block exosome 
release, may have important consequences: specific pro-
teins may be redirected from exosomes to MVs for secre-
tion when exosome production is blocked. Consistent with 
this possibility, Menck et al. (69) showed that exosome- 
enriched proteins, such as CD81 and Wnt, are released in 
association with MVs under n-SMase inhibition. Impor-
tantly, MVs and exosomes derived from many cells share a 
number of common proteins. For example, both MVs and 
exosomes released from brain cells in the course of neuro-
degenerative diseases carry misfolded proteins (A, tau, 
PrP, and -synuclein), which form pathological aggre-
gates (72). Although prolonged treatment of AD mice with 
GW4869 has been shown to reduce exosome levels in brain 
and serum and to decrease A and tau aggregates (57, 60), 
how the n-SMase inhibitor impacts release of tau/A in 
association with MVs has yet to be defined.
Cer-dependent MV biogenesis: role for a-SMase
A specialized type of EV release exists for cells that 
express the ATP receptor, P2X7, which sheds MVs formed 
by evaginations of the surface membrane when the receptor 
is activated. P2X7 receptor-positive cells include monocytes, 
macrophages, mast cells, dendritic cells, T cells, microglia, 
and astrocytes. In myeloid or lymphoid cells, the P2X7 re-
ceptor functions as an ATP-gated nonselective cation chan-
nel and its activation shapes the intensity or duration of 
innate immune and inflammatory responses (73). The 
most relevant consequence of P2X7 channel opening is net 
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K+ efflux and assembly of the NLR family pyrin domain 
containing 3 (NLRP3) inflammasome complexes. These 
complexes enable activation of caspase-1 protease, which 
in turn leads to proteolytic cleavage and release of the pro-
inflammatory cytokines, interleukin (IL)-1, and IL-18 (74).
Before the mechanism of NLRP3 inflammasome assem-
bly was discovered (75), the pioneering work by MacKenzie 
et al. (5) provided evidence that P2X7-induced MV shed-
ding acts as a secretory pathway for IL-1 release. They 
reported that, in THP-1 monocytes, the P2X7 receptor in-
duces formation of blebs, which are subsequently shed as 
MVs into the extracellular space within the first few min-
utes of receptor activation. Importantly, membrane blebs 
accumulate IL-1, which is then packaged into MVs and 
released extracellularly. P2X7-induced membrane bleb-
bing is preceded by loss of plasma membrane asymmetry 
and PS externalization, a commonly accepted marker for 
cell apoptosis. However, alterations of membrane asymme-
try are reversible after brief ATP stimulation, dissociating 
bleb formation and MV shedding from apoptotic cell 
death. Subsequent studies reported that a similar mecha-
nism for IL-1 and IL-18 release occurs in microglial cells 
(71), dendritic cells (76), and macrophages (77), suggest-
ing a general role for P2X7-dependent MV shedding in 
rapid secretion of cytokines lacking a secretory sequence. 
In macrophages, MVs shed in response to P2X7 receptor 
activation also bear active tissue factor and have high pro-
coagulant activity (78).
However, an unsolved question was how signaling by the 
P2X7 receptor led to alterations of the biophysical proper-
ties of the plasma membrane, which, together with actin-
cytoskeleton reorganization, is a prerequisite for membrane 
blebbing and vesiculation. In 2009, Bianco et al. (70) iden-
tified a-SMase as the key enzyme responsible for P2X7-
dependent MV biogenesis at the surface of glial cells 
(microglia and astrocytes). They showed that following 
P2X7 receptor activation, a src-protein tyrosine kinase in-
teracts with the C terminus of the receptor (79) and 
promptly phosphorylates P38 MAP kinase. P38 phosphory-
lation, in turn, induces translocation of a-SMase from 
lysosomes to the plasma membrane outer leaflet, where 
it catalyzes Cer formation from SM (70). As mentioned 
above, SM to Cer conversion perturbs membrane curva-
ture and fluidity, favoring budding of MVs. Specifically, 
redistribution of inverted cone-shaped Cer molecules, syn-
thesized extracellularly, into the inner membrane leaflet 
probably drives membrane evagination (80) (Fig. 1B).
ATP-induced translocation of a-SMase to the plasma 
membrane and SM hydrolysis were recently confirmed by 
an independent group in macrophages (81), the periph-
eral counterpart of brain resident microglia. Immunostain-
ing with an anti-a-SMase antibody revealed the presence of 
the enzyme on the surface of ATP-stimulated macrophages, 
while labeling was limited primarily to the cytoplasm in un-
treated cells. ATP-dependent SM hydrolysis was indicated 
by the release of the [14C]-labeled phosphorylcholine head 
group into the supernatant medium. Importantly, inhibi-
tion of a-SMase expression or activity not only attenuated 
ATP-induced SM hydrolysis but also attenuated release of 
tissue factor-positive MVs, which exhibit pro-coagulant 
activity (81).
Of note, a-SMase-dependent MV formation likely occurs 
at SM-enriched domains of the plasma membrane, where 
the P2X7 receptor localizes (82). As a consequence, cyto-
skeleton/membrane proteins interacting with the long 
cytoplasmic C terminus of the P2X7 receptor can be recruited 
and sorted into MVs. Consistent with this sorting mecha-
nism, MVs released from ATP-stimulated microglia contain 
several proteins previously shown to bind to the P2X7 re-
ceptor C terminus, which are not present in MVs constitu-
tively released by microglia (83).
Recent works suggest that a-SMase can be recruited to 
the plasma membrane to rapidly enhance EV release upon 
stimulation of other surface receptors besides P2X7. Ini-
tially, Truman et al. (84) found that a-SMase is activated in 
response to engagement of surface Fc receptors by oxi-
dized LDL-containing immune complexes and plays a role 
in the release of IL-1 in association with exosomes in the 
human macrophage cell line, U937. This evidence was doc-
umented by reduced exosome and IL-1 secretion from 
cells in which a-SMase was pharmacologically (desipra-
mine) or genetically inhibited (a-SMase siRNA) (84). More 
recently, Marrone et al. (85) reported that a brief stimula-
tion of the transient potential receptor vanilloid type 1 
(TRPV1), also known as vanilloid receptor 1, promotes 
shedding of MVs to the same extent as P2X7 receptor acti-
vation in primary murine microglia. TRPV1 receptor is a 
nonselective cationic channel highly expressed in brain im-
mune cells, which is exogenously activated by capsaicin 
(86) and endogenously activated by inflammatory mole-
cules, such as the signaling lipid, lysophosphatidic acid 
(87). Importantly, p38 MAPK, which is essential for P2X7-
dependent a-SMase translocation onto the plasma mem-
brane, is activated downstream of TRPV1 receptors (88) 
and its inhibition blocks capsaicin-induced MV shedding 
from microglia in vitro and in cortical brain slices (85), 
consistent with a role of a-SMase in TRPV1-dependent MV 
production.
Besides the consolidated role of a-SMase in MV shedding 
from myeloid cells, the enzyme has also been implicated in 
the release of EVs from red blood cells (RBCs), at least un-
der pathological conditions. In 2014, Awojoodu et al. (89) 
reported that plasma membrane stresses and alterations in 
sickle cell disease, an inherited RBC disorder, enhance the 
activation of a-SMase and result in increased EV produc-
tion from erythrocytes. Although erythrocytes do not pos-
sess SMase activity of their own (90) and SMases have been 
reported at low levels in erythrocytes (91, 92), RBCs can be 
exposed to a-SMase secreted by myeloid cells or by vascular 
endothelium (93). RBC-derived EVs display pro-inflamma-
tory activities and promote monocyte adhesion to endothe-
lial cells (89). Importantly, treatment with amitriptyline, an 
indirect inhibitor of a-SMase, reduces EV generation in in 
vitro and in vivo models of sickle cell disease, thereby rep-
resenting a possible treatment to mitigate inflammatory 
processes (93). A very recent study corroborated the role 
of a-SMase in the formation of EVs from RBCs under stress-
ful conditions, i.e., during packed storage (94). Standard 
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blood banking practice allows storage of RBCs up to 42 
days of age. However, as stored human packed RBCs age, 
they release a heterogeneous population of EVs, which 
cause lung inflammation and worse clinical outcomes in 
patients with anemia or hemorrhage. Hoehn et al. (94) 
showed that a-SMase activity is increased in aged compared 
with fresh RBC-derived EVs, whereas a-SMase activity is 
decreased on stored erythrocytes as compared with fresh. 
This suggests that a-SMase changes location and is concen-
trated in EVs over the course of RBC storage. Interestingly, 
the authors demonstrated that inhibition of a-SMase by 
amitriptyline reduces EV production during storage, sup-
porting a primary role of the enzyme in EV biogenesis, and 
leads to a change in the composition of EVs that ultimately 
prevents lung inflammation. In fact, less lung inflamma-
tion was observed in the recipient mice transfused with 
equal numbers of EVs produced from RBCs treated with 
amitriptyline, revealing that a change in a-SMase content 
and/or Cer concentration in EVs likely preserves the integ-
rity of endothelial cells in the lung and prevents endothe-
lial cell apoptosis (94).
Another recent study implicated a-SMase in the release 
of EVs evoked by cigarette smoke (CS) from endothelial 
cells (95). Following exposure to CS, endothelial cells con-
tract their bodies and release EVs from the tips of retract-
ing filopodia-like structures without appreciable cell death. 
Given that Cer production is activated by CS in lung endo-
thelial cells and a-SMase is rapidly activated by stress in the 
cells, Serban et al. (95) interrogated the role of a-SMase in 
the mechanism of CS-induced EV release. They found that 
treatment with imipramine, a functional inhibitor of a-
SMase, markedly decreased CS-induced EV production 
and that a-SMase-null endothelial cells produced fewer EVs 
compared with wild-type cells. The role of a-SMase in EV 
production was corroborated by the observation that mice 
lacking a-SMase (Smpd1/) are characterized by reduced 
levels of EVs in plasma following CS exposure, while mice 
overexpressing a-SMase in endothelial cells display in-
creased levels of circulating EVs. Besides pointing to a key 
role of a-SMase activation in CS-induced EV release, this 
work showed that EVs derived from endothelial cells are 
Cer rich, suggesting that EVs may act as a vehicle for the 
transport of Cer, a highly lipophilic molecule, in aqueous 
environments, such as plasma or bronchoalveolar lavage 
fluid. Also, in human macrophages, CS may promote MV 
shedding through an a-SMase-dependent pathway. This is 
suggested by the work of Li et al. (96) who found that pro-
duction of MVs from human macrophages relies on a se-
ries of regulated steps that include activation of p38 MAPK, 
the enzyme that drives a-SMase translocation onto the 
plasma membrane (70).
While the role of a-SMase in enhancing MV shedding 
in response to danger signals (ATP, TRPV1 agonists) or 
stressful membrane conditions (CS, sickle cell disease, 
packed storage) is established (Table 1), the enzyme may 
not play a role in the constitutive shedding that occurs 
without any stimulation. Indeed, a very recent study showed 
that long exposure of microglial cells or monocytes to pro-
inflammatory or pro-regenerative cytokines (24 h treatment) 
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enhances basal production of MVs, but pharmacological 
inhibition of a-SMase by imipramine or by the structurally 
unrelated indirect inhibitor, siramesine, fails to reduce cy-
tokine-induced MV release. Intriguingly, both constitutive 
release of MVs and cytokine-induced MV release were effi-
ciently blocked by a sub-toxic concentration of actinomy-
cin D, a strong inhibitor of transcription. While ruling out 
a role for a-SMase in constitutive release of MVs, this study 
suggests that cytokines may strengthen constitutive MV 
production through modulation of the transcriptional ac-
tivity in myeloid cells (97).
Galactosyl-Sph-dependent EV biogenesis
A recent study revealed a role for the GSL, galactosyl-
Sph, and its metabolic enzyme, galactosyl-CDase, in the 
control of plasma membrane structure and EV shedding. 
D’Auria et al. (98) highlighted the involvement of galacto-
syl-Sph in alteration of membrane organization and mi-
crovesiculation from oligodendrocytes, the glial cell type 
that deposits myelin along neuronal axons in the central 
nervous system.
Galactosyl-Sph, also known as psychosine, is an inverted 
cone GSL composed of a hydrophobic sphingoid base 
and a hydrophilic polar head group that accumulates in 
brain membranes of Krabbe’s disease, a genetic sphingo-
lipidosis caused by mutations in the psychosine-degrading 
enzyme, galactosyl-CDase. Different from SM, psychosine 
is not ubiquitously present, but generated quite specifi-
cally in oligodendrocytes, where it is considered the main 
SL responsible for demyelination and oligodendrocyte 
loss in Krabbe’s disease. Indeed, psychosine accumulates 
in lipid rafts and disrupts their structures, altering signal-
ing pathways important for oligodendrocyte differentia-
tion and survival (99). However, until recently, no clear 
insights have been provided into how psychosine causes 
demyelination. D’Auria et al. (98) studied psychosine-
mediated membrane disorganization in RBCs and showed 
that psychosine, due to the quite large size of its polar 
head group, affects the organization of the SM-enriched 
domain and elicits outward membrane blebbing and EV 
shedding. It should be noted, however, that, in this study, 
specificity of psychosine action has not been assessed by 
the use of an equal concentration of similarly structured 
lipids, e.g., octyl glucoside or hexadecylglycerol. Findings 
obtained in RBCs were confirmed in oligodendrocytes 
established from Twitcher mice, a model of Krabbe’s dis-
ease, which were more prone to produce MVs than wild-
type cells upon exposure to the psychosine. Vesiculation 
was accompanied by lateral mobility of SM and choles-
terol toward areas in the plasma membrane with high 
focal rigidity, which may introduce focal weak points in 
the myelin sheath contributing to myelin disruption. 
Importantly, this model of MV biogenesis implies that 
MVs do not originate from membrane blebs, which pro-
gressively bud from the plasma membrane and are then 
pinched off from the cell surface, a process that requires 
membrane bending and increased membrane fluidity. 
However, no mechanistic explanation of MV formation is 
provided by the author.
Independent of the underlying mechanisms, psycho-
sine-dependent MV production may spread disease from 
sick to healthy cells. Indeed, while clearing some of the ac-
cumulated SL material via EV secretion, brain cells may 
shuttle pathogenic SLs [e.g., psychosine or proapoptotic 
Cer (56)] to cells that are not intrinsically affected, contrib-
uting to establishing non-cell-autonomous defects (100).
SL CONTENT OF EVs
Comparative analysis of SL composition in exosomes/
MVs and in parental cells
To date, high resolution lipidomic analyses of EVs have 
been reported for a limited number of cell lines (101), thus 
limiting current knowledge of EV lipid composition and 
complexity. However, it is well-established that EVs contain 
lipids, such as aminophospholipids and Cer, which, along 
with GSLs and SM, are the most enriched lipids in EVs of 
different cellular origin (Table 2) (66). The SL content of 
less represented SL species is still very uncertain.
There are major differences in the lipid composition 
of exosomes/MVs compared with whole cell lipid extract 
of parental cells, demonstrating the existence of specific 
mechanisms of lipid sorting into EVs. Interestingly, SM, 
GSLs, and Cer are among EV-enriched lipids compared 
with most donor cells (Table 2) (4, 50, 66, 102–105).
However, Llorente et al. (102) demonstrated that exo-
somes released from reticulocytes and rat basophil leu-
kemia cells exhibit a lower phospholipid-to-protein ratio 
than parental cells. Specifically, they found that most lipid 
classes were more abundant in exosomes, and that the 
relative amounts of specific lipids, such as GSLs, choles-
terol, SM, and PS, were highly enriched in exosomes (102). 
Other studies confirmed enrichment from 1.3- to 2.8-fold 
for SM (4, 50, 66, 102–105) and from 2.0- to 3.8-fold for 
GSLs (50, 102, 103) in exosomes depending on the types of 
donor cells. Exosomes derived from mouse Oli-neu cells 
show less enrichment in SM and GSLs and a much higher 
enrichment in Cer, which is crucial for exosome biogenesis 
inside MVBs (50). Specifically, SM is 1.5 times enriched 
in exosomes isolated from Oli-neu cells, compared with 
parental cells, while it is 2.4 times enriched in PC-3 cell-
derived exosomes (102), 2.3 times enriched in human 
B-cell-derived exosomes (104), 2.8 times enriched in 
mast cell RBL-2H3-derived exosomes (4), and 2.2 times 
enriched in exosomes released from dendritic cells with 
respect to donor cells (105). GSLs are 2.0 times enriched in 
exosomes of Oli-neu cells, compared with their parental 
cells (50), while the enrichment in GSLs is of about 
3.8 times in exosomes from PC-3 cells (102) and even 
18 times in those produced from murine neuroblastoma 
Neuro2a cells (106).
Different methods have been used to analyze the SL 
content of EVs, including TLC, gas LC, and MS. Wubbolts 
et al. (104) were the first group to use MS (in addition to 
TLC) to study the SL content of exosomes released from 
human B-cells. By this approach, they described a large 
 at BIBLIO
TECA ALBERTO
 M
ALLIANI, on Septem
ber 3, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
1332 Journal of Lipid Research Volume 59, 2018
T
A
B
L
E
 2
. 
SL
 c
on
te
n
t i
n
 e
xo
so
m
es
 a
n
d 
en
ri
ch
m
en
t f
ro
m
 th
e 
or
ig
in
at
in
g 
ce
lls
L
ip
id
s
PC
-3
 C
el
ls
  
(1
02
)
O
li-
n
eu
 C
el
ls
  
(5
0)
B
-C
el
ls
 (
10
4)
M
as
t C
el
ls
 (
4)
D
en
dr
it
ic
  
C
el
ls
 (
4)
R
et
ic
ul
oc
yt
es
  
(1
05
)
M
es
en
ch
ym
al
  
St
em
 C
el
ls
 (
10
1)
U
87
 C
el
ls
  
(1
01
)
H
uh
7 
C
el
ls
  
(1
01
)
FE
M
X
1 
 
C
el
ls
 (
15
3)
D
U
14
5 
C
el
ls
  
(1
54
)
V
C
aP
 (
15
4)
L
N
C
aP
  
(1
54
)
%
F
%
F
%
F
%
F
%
F
%
F
%
F
%
F
%
F
%
F
%
F
%
F
%
F
SM
16
.3
2.
4
8.
2
1.
5
23
.0
2.
3
12
2.
8
20
2.
2
8.
4
1.
31
5
1
20
2.
35
4
0.
8
—
4
—
—
—
—
—
—
G
SL
s
0.
78
3.
8
—
2.
0
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1.
8
—
3.
1
—
3
C
er
0.
32
1.
3
—
3.
3
—
—
—
—
—
—
—
—
0.
04
1
0.
2
1
0.
04
0.
25
—
—
—
—
—
—
—
—
D
at
a 
ar
e 
ba
se
d 
on
 th
e 
E
V
 n
et
w
or
k 
da
ta
ba
se
, V
es
ic
le
pe
di
a.
 O
n
ly
 th
e 
re
po
rt
s 
th
at
 a
llo
w
ed
 u
s 
to
 c
al
cu
la
te
 th
e 
ch
an
ge
s 
of
 S
L
s 
in
 E
V
s 
co
m
pa
re
d 
w
it
h
 th
e 
pa
re
n
ta
l c
el
ls
 a
re
 r
ep
or
te
d.
 %
, p
er
ce
n
t o
f t
ot
al
 
lip
id
 q
ua
n
ti
fi
ed
; F
, f
ac
to
r 
of
 e
n
ri
ch
m
en
t f
ro
m
 c
el
ls
 to
 e
xo
so
m
es
 o
r 
M
V
s.
SL enrichment in exosomes and also highlighted similari-
ties between the lipid classes abundant in exosomes and in 
detergent-resistant membranes, the membrane regions 
from which EVs are generated. The use of different meth-
odologies could account for the slightly different SL com-
position of EVs produced by different cell types. However, 
the lipid content may actually vary depending on source 
cell type and even among exosomes and MVs released by 
the same donor cells. A few studies support this possibility: 
i) The comprehensive analysis of lipid composition of 
exosomes, MVs, and source cells in three different cell 
types by Haraszti et al. (101) showing specific enrichment 
in SMs in MVs derived from Huh7 hepatocellular carci-
noma cells or mesenchymal stem cells with respect to MVs 
released by U87 glioblastoma cells (Table 3). Importantly 
this study also revealed that the MVs and exosomes differ in 
their types of lipid contents. Enrichment in glycolipids and 
free fatty acids characterized exosomes, whereas enrich-
ment in Cers and SMs characterized MVs derived from 
Huh7 hepatocellular carcinoma cells as well as mesenchy-
mal stem cells (101). ii) The work by Dang et al. (107) re-
porting significant differences in the lipid composition of 
exosomes secreted across the apical compared with the ba-
solateral plasma membrane of epithelial cells. In particu-
lar, this study showed that SM is more represented in 
exosomes secreted across apical compared with the baso-
lateral plasma membrane (107). iii) SL profiling of human 
oligodendroglioma (HOG) cell-derived exosomes, reveal-
ing differences in the SL composition, in particular of C16-, 
C24-, and C24:1-Cer species; C16-, C24-, and C24:1-dihydroCer 
species; and C16-, C24-, and C24:1-SM species, between 
exosomes released constitutively or under stimulation 
with inflammatory cytokines (108). iv) The work by Ca-
rayon et al. (109) showing that the exosomal content of 
Cer versus SM is significantly increased during reticulo-
cyte maturation. v) The study by Baig et al. (110) demon-
strating that GM3 levels are significantly downregulated in 
MVs derived from syncytiotrophoblasts of preeclampsia 
patients.
SL species in EVs as potential biomarkers
EVs are attracting increasing interest as a source of non-
invasive biomarkers for several diseases, including cancer 
and multiple sclerosis, because these vesicles contain 
pathogenic molecules of donor cells that can be analyzed 
in biofluids (111–113). Interestingly, SLs have recently 
been identified among EV components that are relevant 
for disease diagnosis.
In depth lipidomic analysis of exosomes secreted by a 
colorectal cancer cell line first revealed selective changes in 
SL abundance in EVs compared with parent colon cancer 
cells (114) and suggested that specific exosome SL(s), i.e., 
Cer and SM, could serve as effective diagnostic or prognos-
tic biomarkers for colon cancer. The diagnostic potential 
of exosome SL(s) was then demonstrated by Skotland et al. 
(115), who found that levels of lactosylceramide (d18:1/16:0) 
in urinary exosomes are different between prostate cancer 
patients and healthy controls. Importantly, measurements 
of lactosylceramide in combination with other exosomal 
 at BIBLIO
TECA ALBERTO
 M
ALLIANI, on Septem
ber 3, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
Sphingolipids and extracellular vesicles 1333
lipids were shown to have the capacity to distinguish cancer 
patients from healthy subjects with high sensitivity (93%) 
and specificity (100%) (115).
Another recent work revealed that a distinct SL (C16:0 
sulfatide), a sulfated galactosylceramide with long-chain 
fatty acid, in blood EVs represents a unique indicator of 
multiple sclerosis, a chronic neuroinflammatory disease 
(116). Specifically, using ultra-high-performance LC tan-
dem MS, Moyano et al. (116) detected a significant in-
crease in C16:0 sulfatide in EVs isolated from multiple 
sclerosis patients when compared with healthy subjects.
SL-MEDIATED EV ACTION ON RECIPIENT CELLS
Several lines of evidence point to the involvement of 
exosome GSLs in the pathogenic aggregation of amyloido-
genic peptide A (106) that typically forms extracellular 
aggregates in the brain of subjects affected by AD, the most 
common neurodegenerative disease. GSLs present on the 
exosome surface of Neuro2a cells were shown to form clus-
ters and bind to A peptide. A-GSL complexes, in turn, 
were shown to act as templates for further A aggregation 
and fibril formation (106). In agreement with this study, 
Yanagisawa et al. (117) found that the monosialoganglio-
side, GM1, associates with A in the brain of AD patients. 
On these bases, Yuyama et al. (106) proposed that there may 
be multiple GSLs on exosome membranes that organize 
themselves into specific areas that bind to A and induce 
its assembly. Moreover, cholesterol and SM, which were 
highly enriched in exosomes compared with their parent 
cells, were also shown to promote A assembly via the lateral 
packing of gangliosides on membranes (106, 119, 120).
Emerging evidence indicates that the SL cargo of EVs 
may be responsible for detrimental EV action. In 2012, an 
interesting study by Bieberich’s group revealed the involve-
ment of Cer-enriched exosomes in A-dependent apopto-
sis, which critically contributes to AD (56). The authors of 
this study showed that Cer levels are regulated by n-SMase 
2 in astrocytes and are critical for astrocyte apoptosis caused 
by A, which is not observed in n-SMase 2-deficient cells. 
Astrocyte apoptosis was accompanied by release of Cer- 
enriched exosomes, which propagated a death signal into 
recipient astrocytes not exposed to A protein (56).
A subsequent study confirmed that Cer-enriched exo-
somes mediate cytotoxic effects in recipient cells. Specifi-
cally, exosomes released from HOG cells treated with a 
combination of inflammatory cytokines were found to 
be Cer-enriched and to induce cell death in fresh (naïve) 
HOG cells (108). Interestingly, Cer levels did not increase 
much in donor HOG cells under cytokine treatment, sug-
gesting that Cer is immediately exported out of the cells by 
exosomes after generation.
Another recent work highlighted the involvement of the 
Cer metabolite, S1P, in exosome-mediated neoplastic trans-
formation. Exosome-like particles produced by the intesti-
nal mucosa in response to enterobacteria were shown to 
contain S1P, which favors the recruitment and proliferation 
of inflammatory Th17 T cells in the intestine and promotes 
tumor growth in animal models of colorectal cancer (121).
Finally, Wang et al. (122) identified S1P as the primary 
mediator of endothelial cell exosome actions on hepatic 
stellate cells, responsible for the pathological migration 
and aberrant phenotype of hepatic stellate cells during 
liver fibrosis. Mechanistically, this study revealed that exo-
some-induced hepatic stellate cell migration is dependent on 
exosome adhesion to target cells, which facilitates exosome 
uptake through dynamin-dependent endocytosis (122).
Involvement of SL enzymatic machinery or SL receptors 
in the biological activity of EVs
Accumulating evidence indicates that EVs can influence 
SL metabolism in receiving cells by providing them with 
key SL metabolic enzymes, among other enzymes of lipid 
metabolism borne by EVs (123).
The presence of the S1P-generating enzymes, neutral 
CDase (n-CDase) and SK-1, was first described in EVs shed 
by hepatocarcinoma and carcinoma cultured cells and was 
suggested to contribute to the proangiogenic activity of 
EVs (124). Later on, SK-1 was detected within exosomes 
derived from endothelial cells and, together with its prod-
uct, S1P, identified as the active agent responsible for path-
ological migration on hepatic stellate cells, as mentioned 
above (122). In addition, Zhu et al. (125) found that active 
n-CDase is also released in association with exosomes by 
-pancreatic INS-1 cells exposed to a low concentration 
of inflammatory cytokines. Exosome-packaged n-CDase 
inhibited INS-1-cell destruction induced by a high con-
centration of inflammatory cytokines and the protective 
action was mediated by S1P generation and activation of 
S1P type 2 receptor (S1P2). These findings revealed a 
novel n-CDase-S1P2-dependent mechanism by which exo-
somes produced in response to a low level of inflammatory 
cytokines protect pancreatic -cells from apoptosis (125).
TABLE 3. SL content in MVs and enrichment from the originating cells
Lipids
Bone Marrow-Derived  
Mesenchymal Stem  
Cells (101) U87 Cells (101) Huh7 Cells (101) Platelets (155)
% F % F % F % F
SM 10 2 15,2 0.97 17 2 17 3.4
GSLs — — — — — — — —
Cer 0.48 2 — — 0.68 2.4 0.24 1.5
Data are based on the EV network database, Vesiclepedia. Only the reports that allowed us to calculate the 
changes of SLs in EVs compared with the parental cells are reported. %, percent of total lipid quantified; F, factor of 
enrichment from cells to exosomes or MVs.
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In agreement with this work, hepatocyte-derived exo-
somes were recently shown to be incorporated into target 
hepatocytes and deliver both n-CDase and SK-2 to the cells, 
increasing S1P levels. By this mechanism, exosomes carry-
ing S1P metabolic enzymes induce dose-dependent prolif-
eration of hepatocytes in vitro and contribute to liver repair 
and regeneration after an ischemia/reperfusion injury, a 
major clinical problem that affects liver transplantation 
and other hepatic surgeries (59). Accordingly, exosomes 
produced by mesenchymal stem cells differentiated from 
human pluripotent stem cells were recently shown to exert 
protective and proliferative effects on primary hepatocytes 
and their beneficial action was also ascribed to activation of 
the synthetic machinery for S1P production in hepatocytes 
upon exosome internalization (126). Indeed, either the SK 
inhibitor, SKI-II, or the S1P1 antagonist, VPC23019, com-
pletely abolished the proliferative effect of exosomes on 
primary hepatocytes.
Not only the transfer of SL(s) and/or their enzymatic 
machinery but also the transfer of SL receptors may partici-
pate in the biological action of EVs on target cells. This 
hypothesis has recently been proposed by Pyne et al. (127), 
who found that S1P2 is released from breast cancer cells 
through exosomes, and it is cleaved into a smaller constitu-
tively active form lacking the N terminus (red) into recipi-
ent fibroblasts, where the receptor stimulates the ERK-1/2 
pathway and promotes proliferation. However, to the best 
of our knowledge, experimental data supporting the role 
of exosomal S1P2 cargo in cross-talk between cancer cells 
and fibroblasts are still unpublished. A previous work re-
vealed a specific enrichment in S1P types 3 and 4 receptors 
(S1P3 and S1P4) in MVs and exosomes derived from a 
mammary luminal epithelial cell line overexpressing HER2/
ERBB2 oncogene. Their presence may indeed be relevant 
for the biology of HER2+ tumors, by controlling tumor 
invasion and cell migration. However, their functional 
significance has yet to be evaluated (128).
EV-dependent activation of SL metabolism in target cells
In the last years, evidence has been provided that EVs can 
stimulate SL metabolism in receiving cells not only via the 
transfer of SL enzymatic machinery but also through activa-
tion of SL metabolic enzymes in recipient cells. Data from 
our laboratory showed that lipid species housed on the 
membrane of microglia-derived MVs, through activation of 
contact-mediated signaling pathways, act on neuronal a-
SMase promoting both Cer and Sph production. The latter 
SL increased spontaneous release from excitatory terminals 
in cultured hippocampal neurons by enhancing glutamate 
release probability (129, 130) (Fig. 2B). The stimulation of 
SL metabolism in neurons required the action of neuronal 
a-SMase and was not due to the enzyme transfer from mi-
croglia in association with MVs. In fact, hippocampal cul-
tures established from a-SMase KO mice exposed to MVs 
did not show any significant alteration in miniature excit-
atory postsynaptic current (mEPSC) frequency relative to 
untreated transgenic cultures, whereas wild-type cultures 
treated with MVs displayed an increase in mEPSC frequency 
compared with control neurons (Fig. 2B). Neuronal Sph 
was accountable for MV-mediated potentiation of excitatory 
transmission, as the blockade of Sph production through 
the CDase inhibitor, N-oleoylethanolamine (NOE), strongly 
prevented MV effects on mEPSCs, whereas the blockade of 
S1P synthesis from Sph by the Sph kinase inhibitor, SKI-1, 
was ineffective (Fig. 2A, B). However, in a subsequent study, 
we found that the SL cascade induced by microglial MVs in 
neurons does not stop at Sph, but proceeds to S1P, which 
contributes to enhance glutamate transmission by targeting 
synapsin I, the phosphoprotein controlling synaptic vesicle 
availability for exocytosis (131). The key role of S1P and its 
receptor, S1P3, in controlling synapsin I activity was defined 
by the use of pharmacological inhibitors of the SL cascade 
(i.e, the a-SMase inhibitor, imipramine, the CDase inhibi-
tor, NOE, and the SK inhibitor, SKI-1) as well as S1P receptor 
antagonists (the pan receptor antagonist, S-FTY720- 
vinylphosphonate, the S1P3 antagonist, CAY1044, and the 
S1P1 antagonist, W146) (Fig. 2A, B). These findings were 
corroborated by a recent study reporting that the inhibition 
of a-CDase by the potent inhibitor, ARN14988, completely 
prevents the increase of mEPSC frequency induced by mi-
croglial-derived MVs in cortical slices (85). In this case, MV 
release from microglia was triggered by capsaicin acting on 
TRPV1 receptors, a receptor coupled to P38-MAPK, the en-
zyme that drives a-SMase (see also above). Given that TRPV1 
receptors are antagonized by the broadly used a-CDase 
inhibitor, NOE, the authors employed the CDase inhibitor, 
ARN14988, instead of NOE in order to block a-CDase 
activity. ARN14988 prevented the enhancement of mEPSC 
frequency caused by MVs without interfering with capsaicin-
dependent MV release or MV function on mEPSCs (85).
Importantly, a recent study showed that EVs have the 
epigenetic machinery to target SL metabolism in recipient 
cells. Schatz et al. (132) observed that EVs released by 
a cosmopolitan alga (Emiliania huxleyi) during infection 
with its specific virus (EhV, Phycodnaviridae) have a unique 
lipid composition that differs from that of viruses and 
infected host cells, highly enriched in triacylglycerols. In 
addition, RNA isolation and analysis revealed that EV cargo 
is composed of specific microRNAs that are predicted to 
target SL metabolism (132–134). Together with our find-
ings, this evidence suggests that SL metabolism may be a 
highly conserved pathway activated in recipient cells by EVs 
either through their lipid or miRNA cargoes.
ENDOCANNABINOID-MEDIATED EV ACTION ON 
RECIPIENT CELLS
Another intriguing aspect of lipid involvement in EV 
biological activity concerns the role of endocannabinoids 
(eCBs).
eCBs are lipid mediators that regulate a large number of 
physiological functions in the central and peripheral ner-
vous system (135–137). The two major eCBs, 2-arachidon-
oylglycerol and N-arachidonoylethanolamine (AEA), also 
called anandamide, primarily act as retrograde messen-
gers: typically produced by neurons, eCBs are synthesized 
on demand in response to high synaptic activity and rapidly 
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released extracellularly. In the extracellular space, eCBs 
move toward the presynaptic membrane and activate eCB 
type 1 (CB1) receptors to inhibit neurotransmitter release 
(135, 138–140). However, eCBs are also produced by astro-
cytes and microglial cells (141–143), and control glia-neu-
ron interaction (137, 144) with microglia being the major 
provider of eCBs under inflammatory conditions (145).
A long-standing question in the field of eCB research 
has been how these highly hydrophobic lipids are trans-
ported through the aqueous extracellular environment to 
engage their targets (146, 147). Studies conducted in our 
laboratory uncovered the role of MVs in the transport of 
eCB species outside brain cells (148). We found that EVs 
released from primary microglial cells are enriched in the 
eCB, AEA (while 2-arachidonoylglycerol was under the 
limit of detection), which likely localizes on the vesicle sur-
face. This was indicated by the affinity of a biotinylated 
analog of AEA (biotinyl-AEA) (149) to the MV external 
membrane. We also found that vesicular eCBs are biologi-
cally active: they bind presynaptic CB1 receptors, activate CB1 
Fig. 2. MV-dependent activation of SL metabolism in neurons. A: The SL cascade on the plasma membrane and the targets of genetic/
pharmacological inhibitors. B: The cartoons elucidate the mode of action of MV released by microglial cells on excitatory glutamatergic 
synapses and the effects of genetic/pharmacological inhibitors. Microglial MVs interact with the plasma membrane of neurons through 
surface contact facilitated by receptor-ligand interaction between PS residues (typically exposed on the MV membrane) and PS neuronal 
receptor (in blue). Subsequently, unidentified lipid(s) on the surface of MVs activate a-SMase (translocated to the outer leaflet of plasma 
membrane from lysosomes), thus stimulating SL metabolism in neurons. Sph and S1P have been identified as the SLs responsible for the 
MV effects on the excitatory presynaptic terminal (see also the “a-SMase KO animals,” “CDase inhibitor,” and “SK inhibitor/S1P3 inhibitor/
S1P3 siRNA” panels). Sph acts on the synaptic vesicle-associated SNARE protein, synaptobrevin, activating it and thereby promoting the as-
sembly of the SNARE complex (which is necessary for synaptic vesicle fusion at the presynaptic terminal and, therefore, neurotransmitter 
release). This event increases the probability of neurotransmitter release, empowering excitatory synaptic transmission in neurons targeted 
by MVs. On the other hand, S1P, a SL able to move outside the membranes, travels extracellularly to engage its receptor on the presynaptic 
terminal (likely the S1P3 receptor). S1P3 receptor activation translates into downstream signaling in the target neuron, inducing ERK activa-
tion and synapsin I phosphorylation. Synapsin I is a presynaptic protein responsible for anchoring synaptic vesicles of the reserve pool to the 
actin cytoskeleton, therefore preventing their exocytosis. Dephosphorylated synapsin I binds synaptic vesicles and the actin cytoskeleton, 
tying the two of them together. When phosphorylated, synapsin I breaks the link between vesicles and actin, leaving synaptic vesicles free to 
migrate to the presynaptic terminal, ready for exocytosis upon stimulation. This increases the number of synaptic vesicles that undergo exo-
cytosis when neurotransmitter release is triggered. The actions of genetic/pharmacological inhibitors are described in the a-SMase KO ani-
mals, CDase inhibitor, and SK inhibitor/S1P3 inhibitor/S1P3 siRNA panels.
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receptor downstream signaling, and induce an impairment 
of inhibitory synaptic transmission (Fig. 3). In fact, pri-
mary hippocampal neurons exposed to MVs and recorded 
through patch-clamp electrophysiological technique dis-
played reduced miniature inhibitory postsynaptic current 
frequency compared with control untreated cells, reveal-
ing that MVs reproduce the action of the CB1 receptor 
agonist, WIN 55,212-2 (150, 151), on inhibitory hippocam-
pal synapses (152). Furthermore, the involvement of ve-
sicular AEA in this phenomenon was inferred from the 
ability of the CB1 receptor antagonist, SR141716A (150–152), 
to block the depression of miniature inhibitory postsynaptic 
current frequency evoked by MVs. Finally, MV treatment 
also determined an increase in phosphorylated ERK levels 
in neurons, an event downstream CB1 receptor activation, 
which was again abolished in the presence of SR141716A.
CONCLUSIONS AND FUTURE DIRECTIONS
Progress has been made in the last 10 years in elucidat-
ing how EVs are formed and a fundamental role for Cer 
during formation of membrane negative curvature (away 
from the cytoplasm) has been established, which is neces-
sary for both exosome and MV biogenesis. In the examples 
of EV biogenesis discussed above n- and a-SMase have been 
extensively studied and shown to mediate release of exo-
somes and MVs, respectively. In particular, a clear role for 
a-SMase has been demonstrated in MV release evoked by 
stimulation of various surface receptors or occurring under 
stressful conditions, while a more general role for n-SMase 
in exosome biogenesis has been shown, despite the fact 
that the enzyme does not mediate exosome release in all 
the systems tested. However, a more complex scenario is 
emerging with the n-SMase inhibitor, GW4869 (a common 
tool to block exosome release), enhancing rather than 
blocking production of MVs from the cell surface of epithe-
lial cells.
Consolidated evidence indicates that SLs and their enzy-
matic machinery are enriched in EVs, despite the SL con-
tent of less represented SL species is still uncertain.
Besides attracting interest as potential disease biomark-
ers in cancer and inflammatory diseases, vesicular SLs and 
their metabolic enzymes have been shown to contribute to 
EV action by influencing SL levels in recipient cells. Inter-
estingly EVs may also influence SL activity in receiving cells 
via transfer of microRNAs targeting SL metabolism, as indi-
cated by transcriptomic analysis of EVs produced by pro-
karyotic cells.
We expect that future characterization of EVs in diverse 
cell physiology will have a wide impact in understanding 
biogenesis and signaling functions of these highly con-
served mediators of intercellular communications in mam-
mals.
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